QQ客服 官方微博 反馈留言

	GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
	Wang, Jing-jing; Dong, Mei; He, Xiao-hui; Li, Ye-xiong; Wang, Wei-hu; Liu, Peng; Yang, Jian-liang; Gui, Lin; Zhang, Chang-gong; Yang, Sheng
	2016
卷号	95期号:6页码:e2787
ISSN号	0025-7974
DOI	10.1097/MD.0000000000002787
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6382473
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wang, Jing-jing,Dong, Mei,He, Xiao-hui,et al. GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type[J],2016,95(6):e2787.
APA	Wang, Jing-jing.,Dong, Mei.,He, Xiao-hui.,Li, Ye-xiong.,Wang, Wei-hu.,...&Shi, Yuan-kai.(2016).GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.,95(6),e2787.
MLA	Wang, Jing-jing,et al."GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type".95.6(2016):e2787.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。